bsm-52672R [Primary Antibody]
RUNX2 Recombinant Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: RUNX2

Immunogen Range: 300-450/521


Clonality: Recombinant

Isotype: IgG

Entrez Gene: 860

Swiss Prot: Q13950

Source: Human RUNX2 between 300 to 450 amino acids

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation.

Size: 100ul

Concentration: 1ug/ul

Predicted Molecular Weight: 57


Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Jia Gao. et al. Thymosin beta 10 loaded ZIF-8/sericin hydrogel promoting angiogenesis and osteogenesis for bone regeneration. INT J BIOL MACROMOL. 2024 May;267:131562Read more>>
  • Jingxi Xu. et al. Titanium dioxide nanoparticles oral exposure induce osteoblast apoptosis, inhibit osteogenic ability and increase lipogenesis in mouse. ECOTOX ENVIRON SAFE. 2024 Jun;277:116367Read more>>
VALIDATION IMAGES

Lane 1: Human MDA-MB-231 cell lysates; Lane 2: Human U251 cell lysates probed with RUNX2 Monoclonal Antibody, Unconjugated (bsm-52672R) at 1:500 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.